Insider · SEC Form 4 filer
OrbiMed Genesis GP LLC
Past buys: 3 of 3 beat
Companies
Where they file as an insider
ADARx Pharmaceuticals (ADRX) Director, 10% owner Latest filing Sep 28, 2026
Braveheart Bio (BRVE) Director, 10% owner Latest filing Aug 7, 2026
Prelude Therapeutics (PRLD) Director, 10% owner Latest filing Apr 21, 2026
Keros Therapeutics (KROS) Director Latest filing Nov 21, 2025
Edgewise Therapeutics (EWTX) Director, 10% owner Latest filing Apr 3, 2025
MBX Biosciences (MBX) Director, 10% owner Latest filing Feb 18, 2025
Terns Pharmaceuticals (TERN) Director, 10% owner Latest filing Jul 16, 2024
Disc Medicine (IRON) Director Latest filing Jun 17, 2024
And 2 more companies with older filings.
Track record
Did their buys beat the typical stock?
Open-market buys16
Quarters checked 6 months later3
Beat the typical stock 3 of 3
Quarters too new to check3
3 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
ADARx Pharmaceuticals (ADRX) Bought Sep 28, 2026 · $16.1M · 950,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Braveheart Bio (BRVE) Bought Aug 7, 2026 · $34.9M · 1.94M shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Prelude Therapeutics (PRLD) Bought Apr 21, 2026 · $12.5M · 2.82M shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Edgewise Therapeutics (EWTX) Bought Apr 3, 2025 · $10M · 496,771 shares Beat typical Jun 30, 2025 $13.11 → Dec 31, 2025 $24.82 · +89.3% (typical stock +2.1%)
MBX Biosciences (MBX) Bought Feb 14–18, 2025 · $2.02M · 190,672 shares Beat typical Mar 31, 2025 $7.38 → Sep 30, 2025 $17.50 · +137.1% (typical stock +7.3%)
Disc Medicine (IRON) Bought Jun 17, 2024 · $3M · 83,334 shares Beat typical Jun 30, 2024 $45.07 → Dec 31, 2024 $63.40 · +40.7% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.